Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for COPD: A Randomized, Double-Blind, Multi-Center Parallel-Group Study.

Fernando J. Martinez,Klaus F. Rabe,Gary T. Ferguson,Jadwiga A. Wedzicha,Dave Singh,Chen Wang,K. Rossman,Earl St. Rose,Roopa Trivedi,Shaila Ballal,Patrick Darken,Magnus Aurivillius,Colin Reisner,Paul Dorinsky

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for COPD: A Randomized, Double-Blind, Multi-Center Parallel-Group Study.

2020

Fernando J. Martinez
Klaus F. Rabe
Gary T. Ferguson
Jadwiga A. Wedzicha
Dave Singh
Chen Wang
K. Rossman
Earl St. Rose
Roopa Trivedi
Shaila Ballal
Patrick Darken
Magnus Aurivillius
Colin Reisner
Paul Dorinsky

Rationale: In the Phase III, 52-week ETHOS trial in COPD (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) significantly reduced all-cause mortality versus glyc...

Keywords:

double blind
Formoterol
Budesonide
Medicine
COPD
group study
Glycopyrrolate
all cause mortality
Formoterol Fumarate
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations